Demo de locutor ingles britanico Edward Olive de un cuento infantil App de dibujos animados para Iphone, Ipad, Android y tablets.
http://www.edwardolive.com/audio-locutor-ingles-madrid-espana-english-british-voiceover-spain1.php
Edward Olive video corporativo locutor ingles britanico Madrid España con estudio propio autonnomo
Corporate video voiceover by Edward Olive freelance self employed voice-over actor in Madrid Spain with home studio
http://www.edwardolive.com/audio-locutor-ingles-madrid-espana-english-british-voiceover-spain1.php
For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, “you are not alone.” Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps toward self-management and increased self-confidence. For more than 15 years, Lilly has been at the forefront of support with its Camp Care Package program. This year, Lilly’s diabetes ambassadors, all of whom have type 1 diabetes, will attend camps and share their stories starting July 4 at the Children with Diabetes® Friends for Life® conference.
To view the multimedia release go to:
https://www.multivu.com/players/English/8115051-lilly-diabetes-camp-care-package-speaker-tour/
Getting involved in regenerating \'Life\' back into living. Instead of, just being a game piece who loses, for political, commercial, and religious self-interest moves.
Genvip video corporativo locutor ingles britanico Madrid España con estudio propio autonnomo Edward Olive
Corporate video voiceover by Edward Olive freelance self employed voice-over actor in Madrid Spain with home studio
http://www.edwardolive.com/audio-locutor-ingles-madrid-espana-english-british-voiceover-spain1.php
Locutores en Madrid. Locutores internacionales nativos
Locutores ingleses, dobladores americanos, actores britanicos nativos en Madrid España Edward Olive para voz en off estadounidense, doblaje y locuciones de narrador y personajes para televisión, spots, jingles, publicidad, programas, series, videojuegos, radio, cine, documentales, videos de empresa y videos corporativos.
Precios y tarifas para locución en inglés británico nativo.
http://www.edwardolive.com/homepage_english_british_actor_madrid_barcelona_spain_tv_films_ads_voiceovers.php
English British voice-over actors in Madrid Spain American voice-overs for television series & programmes, radio, corporate videos, commercials, video games, jingles, TV programs, dubbing & feature films voiceovers as narrator and for characters in English, BBC RP and regional UK accents.
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Tuthill announced Fill-Rite nextec™ Intelligence, a first-of-its-kind, smart fuel transfer pump technology that optimizes the fueling of fleet, construction and agricultural equipment.
“Up until now, pumping large volumes of fuel, filling large tanks or a number of vehicles meant you had to stop the pump every 30 minutes to let it cool down. Now, with nextec™ Intelligence, the pump self-manages to maintain optimum performance and continuous operation,” said Tom Carmazzi, Tuthill CEO. “With nextec™ Intelligence in their pumps, fuel operators have advanced technology that predicts, protects and performs.”
Fill-Rite’s initial offering of pumps with nextec™ Intelligence are available now and include pump only (NX3204) and pump, hose and ultra-high flow nozzle (NX3210B). Foot-mount model options will be available in the fourth quarter.
To view the multimedia release go to:
https://www.multivu.com/players/English/8211951-tuthill-fill-rite-nextec-intelligence-smart-fuel-transfer-pump/
Local dating directory with grouped profiles according to ethnicity, religion, community group or special interest with dating intent, Stop wasting time searching in all directons. Enter a free profile and browse local singles with the same background and values as your self in minutes from now.
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
The innovative patented CODA Development technology is protected in the USA and Czech and Slovak Republics by 8 granted patents since 2009. The patent process for the Self Inflating Tire (SIT) further continues with international applications submitted in the EU and 12 more countries including Japan, South Korea, India and China.
Widely patented technology enables CODA Development to immediately offer licenses to interested parties wanting to integrate SIT into their production lines.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63487-coda-self-inflating-tire-inventor-offers-licences
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
